Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update

Janux Therapeutics, Inc. (NASDAQ:JANX) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 7,680,000 shares, an increase of 19.8% from the December 15th total of 6,410,000 shares. Approximately 16.4% of the shares of the company are sold short. Based on an average daily trading volume, of 1,050,000 shares, the days-to-cover ratio is currently 7.3 days.

Janux Therapeutics Stock Performance

Shares of JANX stock traded up $0.11 on Friday, hitting $40.72. The company had a trading volume of 802,219 shares, compared to its average volume of 815,856. The firm has a market cap of $2.14 billion, a P/E ratio of -34.80 and a beta of 3.23. The stock’s 50-day moving average is $53.09 and its two-hundred day moving average is $48.34. Janux Therapeutics has a twelve month low of $7.79 and a twelve month high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The company had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Janux Therapeutics’s revenue for the quarter was down 82.6% compared to the same quarter last year. Equities research analysts predict that Janux Therapeutics will post -1.38 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on JANX shares. Cantor Fitzgerald restated an “overweight” rating and set a $200.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. UBS Group started coverage on Janux Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $69.00 price objective for the company. Stifel Nicolaus upped their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. Finally, BTIG Research upped their price objective on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Janux Therapeutics has a consensus rating of “Buy” and an average price target of $89.90.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 13,334 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $4,507,788.32. This represents a 13.97 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $51.60, for a total value of $1,290,000.00. Following the sale, the chief executive officer now owns 257,054 shares of the company’s stock, valued at approximately $13,263,986.40. The trade was a 8.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 108,334 shares of company stock valued at $6,070,020 in the last ninety days. 29.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Janux Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC grew its stake in Janux Therapeutics by 40.0% in the third quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock valued at $114,587,000 after acquiring an additional 721,563 shares during the period. Logos Global Management LP grew its stake in Janux Therapeutics by 400.0% in the second quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock valued at $31,418,000 after acquiring an additional 600,000 shares during the period. Point72 Asset Management L.P. grew its stake in Janux Therapeutics by 190.2% in the third quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock valued at $17,985,000 after acquiring an additional 259,445 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Janux Therapeutics by 202.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after acquiring an additional 156,675 shares during the period. Finally, Barclays PLC grew its stake in Janux Therapeutics by 496.5% in the third quarter. Barclays PLC now owns 174,061 shares of the company’s stock valued at $7,907,000 after acquiring an additional 144,883 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.